Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha

European Urology

Volumn 57, Issue 3, 2010, Pages 522-529

  Roumeguère, Thierry ^a,b   Zouaoui Boudjeltia, Karim ^a   Babar, Sajida ^c   Nuyens, Vincent ^a   Rousseau, Alexandre ^a   Van Antwerpen, Pierre ^d   Ducobu, Jean ^a   Wespes, Eric ^c   Vanhaeverbeek, Michel ^a  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Atherosclerosis; Erectile dysfunction; LDL; Mox LDL; Myeloperoxidase; PDE5; PDE5 inhibitors

Indexed keywords

INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; TUMOR NECROSIS FACTOR ALPHA; VARDENAFIL;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOTHELIUM CELL; ERECTILE DYSFUNCTION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL;

CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 74649085319     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.030     Document Type: Article

References (51)

1. Roumeguère T., Wespes E., Carpentier Y., Hoffmann P., and Schulman C. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 44 (2003) 355-359
2. Solomon H., Man J.W., and Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89 (2003) 251-253
3. Kang S., Chung N., Kim J., et al. Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 19 (2002) 661-667
4. Barter P. The inflammation: lipoprotein cycle. Atheroscler Suppl 6 (2005) 15-20
5. Chisolm G., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Rad Biol Med 28 (2000) 1815-1826
6. Berliner J., and Heinecke J. The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 20 (1996) 707-727
7. Vita J., Brennan M., Gocke N., et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110 (2004) 1134-1139
8. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
9. Brennan M., Penn M., Van Lente F., et al. Prognostic value of myeloperoxydase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
10. Daugherty A., Dum J., Rateri J., and Heinecke J. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94 (1994) 437-444
11. Zouaoui Boudjeltia K., Legysser I., Van Antwerpen P., et al. Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol 84 (2006) 805-812
12. Zouaoui Boudjeltia K., Roumeguère T., Delree P., et al. Presence of LDL modified by myeloperoxidase in the penis in patients with vascular erectile dysfunction: a preliminary study. Eur Urol 51 (2007) 262-269
13. Kirby M., Jackson G., and Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 59 (2005) 225-229
14. Ahluwalia A., Foster P., Scotland R.S., et al. Anti-inflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci USA 101 (2004) 386-391
15. Nuszkowski A., Gräbner R., Marsche G., Unbehaun A., Malle E., and Hellers R. Hypochlorite-modified low-density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem 276 (2001) 14212-14221
16. - system on intracellular cyclic guanosine monophosphate level of endothelial cells: a link to erectile dysfunction?. Eur Urol 55 (2009) 754-755
17. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109 (2006) 366-398
18. Sliwa K., Woodiwiss A., Kone V.N., et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109 (2004) 750-755
19. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., Kowalczyk D., and Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappa B/nuclear factor-kappa B-sensitive pathway in alveolar epithelial cells. J Pharmacol Exp Ther 300 (2002) 567-576
20. Wespes E., Amar E., Hatzichristou D., et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 49 (2006) 806-815
21. Bella A.J., DeYoung L.X., al-Numi M., and Brock G.B. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 52 (2007) 990-1005
22. Stief C. PDE5 inhibitors: is there more to come besides erectile dysfunction?. Eur Urol 52 (2007) 43-44
23. Havel R.J., Eder H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
24. Moguilevsky N., Garcia-Quintana L., Jacquet A., et al. Structural and biological properties of human recombinant myeloperoxidase produced by Chinese hamster ovary cell lines. Eur J Biochem 19 (1991) 605-614
25. Moguilevsky N., Zouaoui Boudjeltia K., Babar S., et al. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Commun 323 (2004) 1223-1228
26. Rieber A.J., Marr H.S., Comer M.B., and Edgell C.J. Extent of dedifferentiated gene expression in the human endothelium-derived EA.hy926 cell line. Thromb Haemost 69 (1993) 476-480
27. Edgel C.J., Haizlip J.E., Bagnel C.R., et al. Endothelium specific Weibel-Palade bodies in a continuous human cell line EA.hy926. In Vitro Cell Dev Biol 26 (1990) 1167-1172
28. Kim N.N., Huang Y.H., Goldstein I., Bischoff E., and Traish A.M. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 69 (2001) 2249-2256
29. Blount M.A., Beasley A., Zoraghi R., et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66 (2004) 144-152
30. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 21 (2002) 109-116
31. Vlachopoulos C., Rokkas K., Ioakeimidis N., and Stefanidis C. Inflammation, metabolic syndrome, erectile dysfunction and coronary artery disease: common links. Eur Urol 52 (2007) 1590-1600
32. Rosano G.M.C., Aversa A., Vitale C., Fabbri A., Fini M., and Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47 (2005) 214-222
33. Mazo E., Gamidov S., and Iremashvili V. The effect of vardenadil on endothelial function of brachial and cavernous arteries. Int J Impot Res 18 (2006) 464-469
34. Aversa A., Greco E., Bruzziches R., Pili M., Rosano G., and Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot stud. Int J Impot Res 19 (2007) 200-207
35. Aversa A., Vitale C., Volterrani M., et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 25 (2008) 37-44
36. Morano S., Mandosi E., Fallarino M., et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 52 (2007) 1768-1776
37. Behr-Roussel D., Oudot A., Caisey S., et al. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 53 (2008) 1272-1281
38. De Young L.X., Domes T., Lim K., Carson J., and Brock G.B. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 54 (2008) 213-220
39. Gratzke C. Daily use of PDE5-inhibitors: the road to happiness?. Eur Urol 54 (2008) 28-30
40. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999) 718-723
41. Rus H.G., Vlaicu R., and Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127 (1996) 263-271
42. Li A., Dubey S., Varney M.L., Dave B.J., and Singh R.K. IL-8 directly enhanced endothelial cell survival proliferation and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170 (2003) 3369-3376
43. Min C., Yi L., Jiang W., et al. IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells. Cytokine 41 (2008) 9-15
44. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65 (2001) 1-52
45. Haddad J.J., Land S.C., Tarnow-Mordi W.O., et al. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther 300 (2002) 559-566
46. Fernandes J.L., de Oliveira R., Mamoni R., et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease: a randomized placebo-controlled study. Atherosclerosis 196 (2008) 434-442
47. Wu B.N., Chen C.W., Liou S.F., Yeh J.L., Chung H.H., and Chen I.J. Inhibition of proinflammatory tumor necrosis factor-α-induced inducible nitric-oxide synthase by xanthine-based 7-[2-[4-(2-chlorobenzene) piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-3) in rat trachea: the involvement of soluble guanylate cyclase and protein kinase G. Mol Pharmacol 70 (2006) 977-985
48. Browner N., Sellak H., and Lincoln T. Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells. Am J Physiol Cell Physiol 287 (2004) 88-96
49. Wolfsgruber W., Feil S., Brummer S., Kuppinger O., Hofmann F., and Feil R. A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells. Proc Natl Acad Sci USA 100 (2003) 13519-13524
50. El-Galley R., Rutland H., Talic R., Keane T., and Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 166 (2001) 927-931
51. Behr-Roussel D., Gorny D., Mevel K., et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47 (2005) 87-91